Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Drug Profile

Clarithromycin/clofazimine/rifabutin - RedHill Biopharma

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB 204; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Anti-inflammatories; Antibacterials; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Aza compounds; Ethers; Macrolides; Phenazines; Piperidines; Rifamycins; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections; Crohn's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
  • No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis

Most Recent Events

  • 03 Jun 2024 Discontinued - Phase-II for Multiple sclerosis in Israel (PO) (SEC File- 2023 - Redhill Biopharma)
  • 31 Dec 2023 RedHill Biopharma terminates a phase-III clinical trials in Mycobacterium avium complex infections (Treatment-naive) in USA (PO) due to slow recruitment in the trial (NCT04616924) (SEC File- 2023 - Redhill Biopharma)
  • 23 May 2023 RedHill Biopharma terminates a phase-III clinical trials in Nontuberculous mycobacterium (Treatment-naïve) infections in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top